4:04 pm Vertex Pharm: Addition of VX-661 to KALYDECO (ivacaftor) improves lung function in people with CF who are heterozygous for the F508del and G551D mutations in 28-day Phase 2 proof-of-concept study – HedgeChatter

4:04 pm Vertex Pharm: Addition of VX-661 to KALYDECO (ivacaftor) improves lung function in people with CF who are heterozygous for the F508del and G551D mutations in 28-day Phase 2 proof-of-concept study

02 May

4:04 pm Vertex Pharm: Addition of VX-661 to KALYDECO (ivacaftor) improves lung function in people with CF who are heterozygous for the F508del and G551D mutations in 28-day Phase 2 proof-of-concept study

Bystocknews stock, VRTX Comments Off

View todays social media effects on VRTX

View the latest stocks trending across Twitter. Click to view dashboard

See who Vertex is hiring next, click here to view

Author